NEW ORLEANS, June 16 /PRNewswire-FirstCall/ -- Cardinal Health, a
global provider of products and services that improve the safety and
productivity of health care, today announced that it will now manufacture,
compound and distribute Positron Emission Tomography (PET)
radiopharmaceuticals for clinical trials.
The company's new services for the clinical trial market will be
discussed at the Society of Nuclear Medicine's (SNM) 55th Annual Meeting,
taking place in New Orleans, June 14-18.
Cardinal Health owns and operates a network of more than 150 nuclear
pharmacies and operates 25 cyclotron-based PET radiopharmaceutical
manufacturing facilities. These facilities are registered with the Food and
Drug Administration (FDA) to manufacture PET radiopharmaceuticals that are
used by physicians to diagnose various medical conditions.
The company will now offer its PET manufacturing and distribution
services to support clinical trials of new and novel PET agents. Cardinal
Health will also work with pharmaceutical companies and physicians
interested in using PET products to determine the efficacy of therapeutic
medications.
"We're committed to advancing the future of molecular imaging by
helping manufacturers expand the pipeline of new agents that will aid in
the diagnosis and treatment of disease," said John Rademacher, general
manager of nuclear pharmacy services for Cardinal Health. "By supporting
the clinical trial phase of PET drug development, we will also build
strong, long-term partnerships as these products move through the testing
and approval phase and into routine clinical application."
As part of its comprehensive service, Cardinal Health will also submit
drug master files to the FDA for several of the PET agents it manufactures.
These files contain detailed information about the manufacturing and
storing of a specific drug and can help expand the use of PET products
because they allow physicians and others in the pharmaceutical industry to
test PET agents in the treatment or diagnosis of disease without needing to
re-file drug manufacturing information with the FDA.
In addition to operating the largest radiopharmacy network in the
United States, Cardinal Health is also the largest employer of nuclear
pharmacists in the world. The combination of that nuclear pharmacy
expertise and the size of its network allows Cardinal Health to reach more
than 85 percent of all U.S. hospitals within three hours and provide
service and clinical expertise to the nuclear medicine community.
About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an
$87 billion, global company serving the health care industry with products
and services that help hospitals, physician offices and pharmacies reduce
costs, improve safety, productivity and profitability, and deliver better
care to patients. With a focus on making supply chains more efficient,
reducing hospital-acquired infections and breaking the cycle of harmful
medication errors, Cardinal Health develops market-leading technologies,
including Alaris(R) IV pumps, Pyxis(R) automated dispensing systems,
MedMined(TM) electronic infection surveillance service, VIASYS(R)
respiratory care products and the CareFusion(TM) patient identification
system. The company also manufactures medical and surgical products and is
one of the largest distributors of pharmaceuticals and medical supplies
worldwide. Ranked No. 19 on the Fortune 500, Cardinal Health employs more
than 40,000 people on five continents. More information about the company
may be found at http://www.cardinalhealth.com.
SOURCE Cardinal Health, Inc.
 back to top
Related links:
http://www.cardinalhealth.com
CONTACT:
Media: Tara Schumacher, +1-614-757-6250,
Tara.schumacher@cardinalhealth.com, or Investors: Sally Curley,
+1-614-757-7115, sally.curley@cardinalhealth.com, both of
Cardinal Health
|
